Number of the records: 1
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
Title ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4) / Drgoňa L. ... [et al.] Another responsib. Drgoňa, Ľuboš (Bibliographic antecedent) Redakcia Onkológia (Adapter) Note Clinical microbiology and infections, Jun 24, Suppl.2 (2018), S83-S94 In Onkológia. -- ISSN 1336-8176. -- Roč. 13, č. 3 (2018), s. 221 Call number C 3069 MeSH Subject infekcie oportúnne - etiológia - prevencia a kontrola terapia molekulárne cielená - účinky nežiaduce terapia biologická - účinky nežiaduce bezpečnosť lektín 2 viažuci kyselinu sialovú, podobný imunoglobulínu - antagonisty a inhibítory Ki-1 antigén - antagonisty a inhibítory ADP-ribozyl cykláza 1 - antagonisty a inhibítory antigény CD40 - antagonisty a inhibítory rodina signálnych molekúl aktivácie lymfocytov - antagonisty a inhibítory receptory CCR4 - antagonisty a inhibítory Keywords inotuzumab ozogamicin * brentuximab vedotín * daratumumab * lucatumumab * anti-SLAMF7/CD319 * elotuzumab * mogamulizumab Language English Country Slovakia Database ARTICLES 
article
Number of the records: 1